MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 18, 2006; DOI: 10.1124/mol.106.025007


0026-895X/06/7002-589-603$20.00
Mol Pharmacol 70:589-603, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025007v1
70/2/589    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yacoub, A.
Right arrow Articles by Dent, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yacoub, A.
Right arrow Articles by Dent, P.

OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells

Adly Yacoub, Margaret A. Park, David Hanna, Young Hong, Clint Mitchell, Aditi P. Pandya, Hisashi Harada, Garth Powis, Ching-Shih Chen, Costas Koumenis, Steven Grant, and Paul Dent

Departments of Biochemistry (A.Y., M.A.P., D.H., Y.H., C.M., A.P.P., S.G., P.D.), Medicine (H.H., S.G.), and Radiation Oncology (A.Y., P.D.), Virginia Commonwealth University, Richmond, Virginia; Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio (C.-S.C.); Department of Radiation Oncology, Wake Forest University, Winston Salem, North Carolina (C.K.); and Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas (G.P.)

We determined one mechanism by which the putative phosphoinositide-dependent kinase (PDK)-1 inhibitor 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}acetamide (OSU-03012) killed primary human glioma and other transformed cells. OSU-03012 caused a dose-dependent induction of cell death that was not altered by p53 mutation, expression of ERBB1 vIII, or loss of phosphatase and tensin homolog deleted on chromosome 10 function. OSU-03012 promoted cell killing to a greater extent in glioma cells than in nontransformed astrocytes. OSU-03012 and ionizing radiation caused an additive, caspase-independent elevation in cell killing in 96-h viability assays and true radiosensitization in colony formation assays. In a cell type-specific manner, combined exposure to OSU-03012 with a mitogen-activated protein kinase kinase 1/2 inhibitor, phosphoinositide 3-kinase/AKT inhibitors, or parallel molecular interventions resulted in a greater than additive induction of cell killing that was independent of AKT activity and caspase function. OSU-03012 lethality as a single agent or when combined with signaling modulators was not modified in cells lacking expression of BIM or of BAX/BAK. OSU-03012 promoted the release of cathepsin B from the lysosomal compartment and release of AIF from mitochondria. Loss of BH3-interacting domain (BID) function, overexpression of BCLXL, and inhibition of cathepsin B function suppressed cell killing and apoptosis-inducing factor (AIF) release from mitochondria. In protein kinase R-like endoplasmic reticulum kinase-/- cells, the lethality of OSU-03012 was attenuated which correlated with reduced cleavage of BID and with suppression of cathepsin B and AIF release into the cytosol. Our data demonstrate that OSU-03012 promotes glioma cell killing that is dependent on endoplasmic reticulum stress, lysosomal dysfunction, and BID-dependent release of AIF from mitochondria, and whose lethality is enhanced by irradiation or by inhibition of protective signaling pathways.


Received March 28, 2006; accepted April 18, 2006

Address correspondence to: Dr. Paul Dent, Department of Biochemistry, Massey Cancer Center Virginia Commonwealth University, Richmond, VA 23298-0058. E-mail: pdent{at}hsc.vcu.edu


Related articles in MolPharm:

OSU-03012 in the Treatment of Glioblastoma
James A. McCubrey, Michelle M. LaHair, and Richard A. Franklin
MolPharm 2006 70: 437-439. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
Cancer Res.Home page
Y.-C. Wang, S. K. Kulp, D. Wang, C.-C. Yang, A. M. Sargeant, J.-H. Hung, Y. Kashida, M. Yamaguchi, G.-D. Chang, and C.-S. Chen
Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
Cancer Res., April 15, 2008; 68(8): 2820 - 2830.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S.-C. Weng, Y. Kashida, S. K. Kulp, D. Wang, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor
Mol. Cancer Ther., April 1, 2008; 7(4): 800 - 808.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. A. Park, A. Yacoub, M. Rahmani, G. Zhang, L. Hart, M. P. Hagan, S. K. Calderwood, M. Y. Sherman, C. Koumenis, S. Spiegel, et al.
OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed Cells
Mol. Pharmacol., April 1, 2008; 73(4): 1168 - 1184.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Yacoub, P. Gupta, M. A. Park, M. Rhamani, H. Hamed, D. Hanna, G. Zhang, D. Sarkar, I. V. Lebedeva, L. Emdad, et al.
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling
Mol. Cancer Ther., February 1, 2008; 7(2): 314 - 329.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Mitchell, M. A. Park, G. Zhang, A. Yacoub, D. T. Curiel, P. B. Fisher, J. D. Roberts, S. Grant, and P. Dent
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells
Mol. Cancer Ther., December 1, 2007; 6(12): 3101 - 3112.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Mitchell, P. Kabolizadeh, J. Ryan, J. D. Roberts, A. Yacoub, D. T. Curiel, P. B. Fisher, M. P. Hagan, N. P. Farrell, S. Grant, et al.
Low-Dose BBR3610 Toxicity in Colon Cancer Cells Is p53-Independent and Enhanced by Inhibition of Epidermal Growth Factor Receptor (ERBB1)-Phosphatidyl Inositol 3 Kinase Signaling
Mol. Pharmacol., September 1, 2007; 72(3): 704 - 714.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Zhang, A. Suvannasankha, C. D. Crean, V. L. White, A. Johnson, C.-S. Chen, and S. S. Farag
OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms
Clin. Cancer Res., August 15, 2007; 13(16): 4750 - 4758.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Mitchell, M. A. Park, G. Zhang, S. I. Han, H. Harada, R. A. Franklin, A. Yacoub, P.-L. Li, P. B. Hylemon, S. Grant, et al.
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
Mol. Cancer Ther., February 1, 2007; 6(2): 618 - 632.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Yacoub, W. Hawkins, D. Hanna, H. Young, M. A. Park, M. Grant, J. D. Roberts, D. T. Curiel, P. B. Fisher, K. Valerie, et al.
Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment
Mol. Pharmacol., January 1, 2007; 71(1): 259 - 275.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. A. McCubrey, M. M. LaHair, and R. A. Franklin
OSU-03012 in the Treatment of Glioblastoma
Mol. Pharmacol., August 1, 2006; 70(2): 437 - 439.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics